Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932452 | 0.84 | DRD2 (0.54) | LTA4HEPHX2FFAR1DRD2DRD4 | |
| SCHEMBL4521863 | 0.84 | KCNA3 (0.59) | LTA4HEPHX2FFAR1DRD2DRD4 | |
| SCHEMBL4523221 | 0.83 | LTA4H (0.66) | LTA4HEPHX2FFAR1BCHEDRD2 | |
| SCHEMBL5380612 | 0.80 | FFAR1 (0.55) | LTA4HEPHX2FFAR1TDP1PPARG | |
| SCHEMBL4692389 | 0.79 | LTA4H (0.70) | LTA4HEPHX2FFAR1BCHE | |
| SCHEMBL31725799 | 0.79 | CA12 (0.45) | LTA4HEPHX2BCHE | |
| SCHEMBL14463902 | 0.78 | FFAR1 (0.62) | LTA4HEPHX2FFAR1DRD2DRD4 | |
| SCHEMBL9808291 | 0.78 | KCNH2 (0.57) | LTA4HDRD2DRD4DRD3KCNH2 | |
| SCHEMBL4521402 | 0.76 | KCNH2 (0.49) | LTA4HDRD2DRD4DRD3KCNH2 | |
| SCHEMBL4522391 | 0.75 | FFAR1 (0.61) | LTA4HEPHX2FFAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | LTA4H 281/4885EPHX2 214/4885FFAR1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.